Molnupiravir for treating COVID-19 authorized by Medicines Agency

The pharmaceutical product Molnupiravir, 200 mg capsules, which is used to treat minor and moderate forms of COVID-19, was authorized by the Medicines Commission of the Medicines and Medical Devices Agency. The price of the drug will be authorized as a matter of urgency. After the Order is published in the Official Gazette, the medicine will be available from drugstores, IPN reports.

Last month, the Agency authorized two producers to import the antiviral drug by issuing permits for importing unregistered medicines. This way, Molnupiravir can be already found in some of the drugstores.

Molnupiravir is indicated for the treatment of mild and moderate forms of COVID-19 in adults with a positive diagnostic SARS-COV-2 test and with at least a risk factor for developing a severe form of disease, such as obesity, old age, diabetes and heart disease.

The antiviral drug must be taken immediately after the diagnosis is made and during five days of the appearance of the symptoms as clinical studies showed that the medicine is more effective when it is administered at the onset of the disease.

Вы используете модуль ADS Blocker .
IPN поддерживается от рекламы.
Поддержи свободную прессу!
Некоторые функции могут быть заблокированы, отключите модуль ADS Blocker .
Спасибо за понимание!
Команда IPN.